Wade May, MD
Cardiovascular Disease · Lafayette, LANPI 1861682239
Payments from drug & device makers
Across 461 payments — averaging $651.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$116K
- Merck$93K
- CSL Behring$63K
- Amgen$17K
- Sanofi-aventis U.S. LLC$5K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $5K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 92 | $116,217 |
| Merck | 41 | $92,962 |
| CSL Behring | 45 | $62,588 |
| Amgen | 50 | $16,597 |
| Sanofi-aventis U.S. LLC | 10 | $5,306 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,078 |
| Abiomed | 14 | $1,044 |
| Boehringer Ingelheim | 19 | $951 |
| Johnson & Johnson | 57 | $835 |
| E.r. Squibb & Sons, L.L.C. | 33 | $605 |
| Pfizer | 30 | $461 |
| Silk Road Medical, Inc. | 2 | $276 |
| Amarin Pharma, Inc. | 11 | $221 |
| AstraZeneca | 11 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $130 |
| Boston Scientific | 2 | $102 |
| Medtronic(2 entities) | 4 | $101 |
| Kestra Medical Technology Services, Inc. | 1 | $58 |
| Edwards Lifesciences | 1 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Philips North America LLC | 1 | $45 |
| Scpharmaceuticals Inc. | 3 | $43 |
| Bayer | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Cleerly, Inc. | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Novo Nordisk | 1 | $17 |
| Gilead | 1 | $16 |
| Cvrx, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
How this compares
$300,143 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Lafayette
- Corwin ThomasLafayette$30K
- Brent RochonLafayette$21K
- Ghiath MikdadiHammond$5.7M
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
- William SmithRuston$694K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.